Disc Medicine announces $350 million public offering with underwriter option
Disc Medicine plans an underwritten public offering of common stock and pre‑funded warrants worth $350 million. Jefferies, Leerink Partners, Morgan Stanley and Cantor are acting as joint book‑running managers. The company will use the net proceeds, together with existing cash, to fund research and clinical development of its product candidates, including potential commercialization of bitopertin for EPP and XLP, and for working capital. Underwriters have a 30‑day option to purchase up to an additional $52.5 million of shares.
Why it matters
The capital raise is intended to extend Disc Medicine’s cash runway and support its clinical programs, which could affect the company’s future revenue potential (the company states this in its press release). The additional underwriter option may increase dilution if exercised.
Key facts
- 1Disc Medicine announced a $350 million public offering of common stock and pre‑funded warrants. stocktitan.net
- 2Jefferies, Leerink Partners, Morgan Stanley and Cantor are acting as joint book‑running managers for the offering. stocktitan.net
- 3Proceeds will fund research and clinical development of product candidates, including potential commercialization of bitopertin for erythropoietic protoporphyria (EPP) and X‑linked protoporphyria (XLP), and will also support working capital and general corporate purposes. stocktitan.net
- 4Underwriters have a 30‑day option to purchase an additional $52.5 million of shares. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.